Medical information for Relvar Ellipta including therapeutic indications, usage and dosage instructions, plus benefits and possible risk factors.

Apr 10, 2025 · Relvar Ellipta is an inhaler for treating asthma and chronic obstructive pulmonary disease (COPD). In asthma, it is used for regular treatment of patients from 12 years of age: …

Relvar Ellipta (fluticasone furoate/vilanterol) is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal …

Relvar Ellipta should be used every day and not only when you have breathing problems or other symptoms of COPD and asthma. It should not be used to relieve a sudden attack of …

Relvar Ellipta should be used every day and not only when you have breathing problems or other symptoms of COPD and asthma. It should not be used to relieve a sudden attack of …

In 2013, the drug was approved for use in the United States by the Food and Drug Administration (FDA) for long-term maintenance treatment of airflow obstruction in people with COPD, …

Jan 7, 2025 · Vilanterol is a selective long-acting beta2-adrenergic agonist (LABA) with inherent 24-hour activity for once daily treatment of COPD and asthma. Its pharmacological effect is …

Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV 1 <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular …

Relvar contains a unique combination of long-lasting molecules – fluticasone furoate and vilanterol. 1 This means that once-daily dosing with Relvar provides continuous 24-hour …

Relvar Ellipta (GSK) is a dry powder inhaler that contains a corticosteroid (fluticasone furoate) and a long-acting beta2 agonist (vilanterol trifenatate). It is licensed for once-daily use as …